Dr. Gregory Egnaczyk, MD
NPI: 1174513733
Total Payments
$72,631
2024 Payments
$595.18
Companies
22
Transactions
211
Medicare Patients
7,322
Medicare Billing
$570,946
Payment Breakdown by Category
Consulting$63,751 (87.8%)
Food & Beverage$5,803 (8.0%)
Travel$3,076 (4.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $63,751 | 28 | 87.8% |
| Food and Beverage | $5,803 | 171 | 8.0% |
| Travel and Lodging | $3,076 | 12 | 4.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $65,629 | 83 | $0 (2024) |
| Boston Scientific Corporation | $5,314 | 11 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $601.72 | 78 | $0 (2024) |
| Medtronic Vascular, Inc. | $312.90 | 3 | $0 (2018) |
| Amgen Inc. | $163.99 | 11 | $0 (2020) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $153.18 | 2 | $0 (2023) |
| Alnylam Pharmaceuticals Inc. | $136.02 | 2 | $0 (2024) |
| Merck Sharp & Dohme LLC | $56.24 | 4 | $0 (2024) |
| ABIOMED | $40.76 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $38.22 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $595.18 | 46 | Novartis Pharmaceuticals Corporation ($196.10) |
| 2023 | $7,537 | 39 | Abbott Laboratories ($4,478) |
| 2022 | $29,903 | 20 | Abbott Laboratories ($27,507) |
| 2021 | $19,590 | 14 | Abbott Laboratories ($19,575) |
| 2020 | $2,820 | 11 | Abbott Laboratories ($2,700) |
| 2019 | $798.75 | 22 | Abbott Laboratories ($569.93) |
| 2018 | $3,111 | 27 | Abbott Laboratories ($2,769) |
| 2017 | $8,276 | 32 | Abbott Laboratories ($7,943) |
All Payment Transactions
211 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.63 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $4.94 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/28/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $4.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/28/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $2.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/03/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $5.55 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/17/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/12/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/12/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $2.30 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $5.80 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/28/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $4.60 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $5.21 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $4.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $2.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/13/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $5.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/13/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $2.04 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/17/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $5.37 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $7.91 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/04/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/02/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Not Applicable | ||||||
| 06/26/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $4.79 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/26/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $2.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/30/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Diabetes | ||||||
| 05/29/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 1,531 | 2,163 | $385,917 | $122,289 |
| 2022 | 23 | 1,676 | 2,251 | $395,830 | $122,007 |
| 2021 | 21 | 2,040 | 2,832 | $511,524 | $163,241 |
| 2020 | 24 | 2,075 | 2,928 | $479,212 | $163,409 |
Total Patients
7,322
Total Services
10,174
Medicare Billing
$570,946
Procedure Codes
108
All Medicare Procedures & Services
108 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 289 | 439 | $116,755 | $38,188 | 32.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 66 | 221 | $57,018 | $20,723 | 36.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 73 | 204 | $36,516 | $12,713 | 34.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 48 | 54 | $27,081 | $7,242 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 45 | 55 | $19,599 | $7,017 | 35.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 136 | 136 | $24,888 | $6,595 | 26.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 128 | 130 | $23,790 | $6,381 | 26.8% |
| 93750 | Evaluation of lower heart chamber assist device | Facility | 2023 | 32 | 133 | $16,226 | $4,197 | 25.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 28 | 42 | $8,232 | $2,929 | 35.6% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 33 | 34 | $9,350 | $2,827 | 30.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $5,803 | $1,815 | 31.3% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 65 | 86 | $5,504 | $1,614 | 29.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $5,130 | $1,436 | 28.0% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2023 | 14 | 14 | $4,704 | $1,430 | 30.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 20 | 22 | $3,960 | $1,393 | 35.2% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 17 | 18 | $4,914 | $1,232 | 25.1% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 12 | 12 | $2,556 | $707.88 | 27.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 106 | 108 | $2,268 | $646.40 | 28.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 65 | 66 | $2,706 | $613.25 | 22.7% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 35 | 35 | $1,610 | $484.75 | 30.1% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 42 | 42 | $1,260 | $352.32 | 28.0% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 48 | 60 | $1,080 | $330.99 | 30.6% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 18 | 18 | $990.00 | $280.16 | 28.3% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 30 | 31 | $930.00 | $257.57 | 27.7% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 87 | 106 | $848.00 | $252.00 | 29.7% |
About Dr. Gregory Egnaczyk, MD
Dr. Gregory Egnaczyk, MD is a Advanced Heart Failure and Transplant Cardiology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2005. The National Provider Identifier (NPI) number assigned to this provider is 1174513733.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Egnaczyk, MD has received a total of $72,631 in payments from pharmaceutical and medical device companies, with $595.18 received in 2024. These payments were reported across 211 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($63,751).
As a Medicare-enrolled provider, Egnaczyk has provided services to 7,322 Medicare beneficiaries, totaling 10,174 services with total Medicare billing of $570,946. Data is available for 4 years (2020–2023), covering 108 distinct procedure/service records.
Ad
Practice Information
- Specialty Advanced Heart Failure and Transplant Cardiology
- Other Specialties Cardiovascular Disease
- Location Cincinnati, OH
- Active Since 10/25/2005
- Last Updated 10/27/2020
- Taxonomy Code 207RA0001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174513733
Products in Payments
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $32,072
- HeartMate 3 Left Ventricular Assist Device (Device) $19,575
- Circulatory Support (Device) $7,774
- HeartMate 3 Left Ventricular Dev (Device) $5,255
- General - Therapies (Device) $2,277
- HeartMate (Device) $620.04
- ENTRESTO (Drug) $538.42
- CardioMEMS HF System (Device) $183.62
- CoreValve Evolut (Device) $169.91
- Corlanor (Drug) $163.99
- LifeVest (Device) $153.18
- Mitra Clip system (Device) $149.43
- HeartWare HVAD (Device) $142.99
- ONPATTRO (Drug) $136.02
- RESONATE (Device) $114.46
- LATITUDE (Device) $85.55
- LEQVIO (Drug) $63.30
- VERQUVO (Drug) $56.24
- Impella (Device) $40.76
- VYNDAQEL (Drug) $26.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Advanced Heart Failure and Transplant Cardiology Doctors in Cincinnati
Rachel Garcia, Md, MD
Advanced Heart Failure and Transplant Cardiology — Payments: $77,841
Advanced Heart Failure and Transplant Cardiology $77,841
Stephanie Dunlap, D.o, D.O
Advanced Heart Failure and Transplant Cardiology — Payments: $7,752
Advanced Heart Failure and Transplant Cardiology $7,752
Juliane Vierecke, Md, MD
Advanced Heart Failure and Transplant Cardiology — Payments: $4,342
Advanced Heart Failure and Transplant Cardiology $4,342
George Blake, Md, MD
Advanced Heart Failure and Transplant Cardiology — Payments: $3,747
Advanced Heart Failure and Transplant Cardiology $3,747
Ahmed El-Moghraby, M.d, M.D
Advanced Heart Failure and Transplant Cardiology — Payments: $1,003
Advanced Heart Failure and Transplant Cardiology $1,003